Business Wire

SOSAFE

24.5.2024 10:41:26 CEST | Business Wire | Press release

Share
SoSafe Introduces The Human Risk OS™, Leading the Category Evolution Towards Human Risk Management

SoSafe, Europe’s largest security awareness and human risk management vendor, has announced the launch of their pioneering Human Risk Operating System, The Human Risk OS™, a set of capabilities designed to help customers identify, quantify, monitor, and intervene on human security risk. SoSafe has also presented new capabilities to its Sofie Human Security Copilot, an AI-powered multi-channel agent built entirely on advanced Large Language Models, as well as incremental updates to its flagship product offering such as next-level personalized learning, behavioral phishing simulation, novel security operations and 3rd party data integrations. With that, SoSafe is leading the category evolution from security awareness to human risk management in response to escalating cyber threats and the need for security strategies to address human risk more holistically.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524947770/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SoSafe launches The Human Risk OS™, bringing together all of SoSafe’s security offerings into a single cohesive platform that helps security teams to drive a holistic human risk management strategy and foster security cultures. Copyright: SoSafe GmbH

Dr Niklas Hellemann, Psychologist and CEO at SoSafe: “To achieve real risk reduction and meet the demands of security leaders, basic awareness measures alone don’t cut it. While traditional and generic awareness programs focus on awareness and knowledge transfer–educating individuals about potential threats and instructing them on response strategies–this approach often falls short in today’s dynamic environment. The evolving landscape requires an evolution to holistic human risk management, which prioritizes the outcomes and the drivers of behavior and helps to sustainably mitigate human risks.”

The Human Risk OS brings together all of SoSafe’s security offerings into a single cohesive platform that helps security teams to drive a holistic human risk management strategy and foster security cultures. It focuses on proactively managing security risks through real-time risk detection and continuous analyses, provides enhanced behavioural insights and recommends targeted interventions to customize and optimize defensive responses.

Its three core elements are:

  • Human Behavior Sensors measure an organization’s digital activities, behaviors, and security culture, creating individual and group-level profiles of security behavior.
  • The Human Security Index processes this tracked data and additional contextual information such as level of seniority, tenure, digital access, and functional criticality to create a single index that summarizes security performance for groups and organizations. This score allows organizations to quickly identify concern areas, track progress, and evolution over time, and the impact of different possible interventions.
  • The Intervention Hub suggests intervention strategies to mitigate human-related security risks and drive behavioral change and healthy security.

Gonçalo Gaiolas, CPO at SoSafe: “We believe in the power of people in the fight against cybercrime. With The Human Risk OS™, organizations invest in more than just a security solution—they invest in a proactive approach to mitigating human-centric risk and securing their organization's future by putting people at the very center of their efforts. We empower organizations to drive behavioral change and build security cultures by identifying, quantifying, actively managing, and reducing their human risk and by focusing on efficiency to relieve the pressure on overstretched security teams.”

SoSafe also introduced additional capabilities to its “Sofie Human Security Copilot”, an AI-powered multi-channel agent built to meaningfully reduce human risk. Sofie supports security professionals and users with rapid threat awareness, situational awareness, and zero-level security and compliance support. Security leaders can now incorporate organisational policies and specifics into their responses. Built on advanced large language models and featuring an engaging interface, Sofie provides answers to support questions at any time, sends urgent security alerts, and educates users on security best practices, all customized to specific organizational needs and policies.

Unlike other conversational AI-solutions, Sofie focuses on making each interaction with the end user a learning moment in their daily work environment, not just delivering informative content, but also aiming to change behavior.

Gonçalo Gaiolas: “Cybercriminals are already harnessing the power of AI to enhance their social engineering attacks. It's time to use the full potential of AI on the defensive side as well. Our AI-powered multi-channel agent ‘Sofie’ demonstrates the power of AI for cyber defenses: It’s a multifunctional tool that makes security information accessible to everyone anytime, provides learning opportunities in every interaction, and supports security administrators with content and communication, automating responses to free up their team’s capacity. ‘Sofie’ makes cybersecurity part of our everyday work, manifesting security cultures as the most essential part of holistic human risk management.”

Ilona Simpson, longstanding CIO and Executive Advisor at SoSafe: “SoSafe’s Human Risk OS™ and Sofie help security leaders to efficiently drive a human risk management strategy that sustainably mitigates risk. Based on behavioral data and fueled with new technology, SoSafe simplifies where others complicate, making it easy for security professionals to strengthen the human layer as the most versatile part of our defense strategy. SoSafe's focus on automation and efficiency not only saves security teams significant time but also amplifies their results, enhancing overall security posture.”

SoSafe presented its product innovations “The Human Risk OS™” and “Sofie Human Security Copilot” with its new capabilities during a launch event on May 23rd in Cologne, Germany and via livestream in front of more than 300 industry guests.

About SoSafe

SoSafe, founded by a team of behavioral scientists and technology experts, is the largest security awareness and human risk management vendor based in Europe. SoSafe is empowering over 4700 customers worldwide to effectively mitigate cyber risk. With a unique human-centric approach grounded in behavioral science, SoSafe enhances secure behavior across organizations, making it intuitive and second nature. The platform is designed to strengthen digital self-defense by creating robust security cultures that actively involve employees in mitigating human risks. By leveraging psychology and advanced technology and AI, it enables security professionals to effectively identify, prioritize, manage, and ultimately reduce their human risk. The SoSafe team now consists of more than 450 employees in seven locations: Cologne (headquarters), Amsterdam, Berlin, London, Paris, Lisbon, and Munich.

Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240524947770/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye